This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Exact Sciences' Colon Cancer Screening Test Results Published in NEJM

The pivotal study of Exact Sciences' (EXAS - Get Report) Cologuard stool-based DNA screening test for colon cancer were published in the New England Journal of Medicine tonight, one day earlier than expected due to an embargo break by the Mayo Clinic. 

There are a lot of numbers to go over so let's get to it.

The sensitivity of Cologuard to detect colon cancer was 92.3% compared to 73.8% for fecal immunochemical testing (FIT), the comparator used in the study. 

The sensitivity to detect advanced pre-cancer was 42.4% for Cologuard compared 23.8% for FIT. For polyps with high-grade dysplasia, the comparative sensitivities were 69.2% for Cologuard and 46.2% for FIT. 

Exact Sciences' previously disclosed Cologuard's superiority to detect colon cancer and pre-cancerous lesions compared to FIT. The data in the NEJM study bear out this finding, with statistically significant results. The study authors note that Cologuard's superior sensitivity was due to the screening test's DNA marker and algorithm. The performance of Cologuard's hemoglobin component was similar to FIT. 

There were more false positives with Cologuard than FIT in the study. Cologuard specificity was 86.6% compared to 94.9% for FIT. 

The number of people required to be screened to detect 1 cancer would be 154 with colonoscopy, 166 with Cologuard and 208 with FIT, the study concludes.

To detect a single precancerous polyp would require screening of 13 people by colonoscopy, 31 by Cologuard and 55 by FIT. 

Cologuard was associated with a higher rate of technical failure. Of the 11,016 people evaluable in the study, 689, or 6%, had Cologuard results excluded due to stool samples that could not be evaluated or technical failure. By comparison, only 0.3% of FIT results were excluded. 

The study authors conclude Cologuard was associated with a 27% relative increase in the rate of detection of stage I to stage III colon cancer and a 78% relative increase in the detection of advanced precancerous lesions compared to FIT. 

An accompanying editorial in the NEJM concurs with the author's conclusions about the superior sensitivity of Cologuard over FIT but includes cautious remarks about the former's specificity and the higher technical failure rate, which raises the risk that cancers might be missed. 

The higher false positive rate for Cologuard is an "important consideration when determining the appropriate interval for screening," the editorial states.

Cologuard is expected to cost more than FIT, so any recommendation of more frequent testing interval could cause reimbursement headaches and lower adoption.

The FDA is convening an advisory panel to review Cologuard on March 27. 

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
EXAS $22.49 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%
TSLA $185.00 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs